As of 2025-12-24, the EV/EBITDA ratio of Cytosorbents Corp (CTSO) is -3.96. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CTSO's latest enterprise value is 50.99 mil USD. CTSO's TTM EBITDA according to its financial statements is -12.86 mil USD. Dividing these 2 quantities gives us the above CTSO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 19.3x - 22.0x | 21.0x |
| Forward P/E multiples | 21.7x - 24.4x | 22.8x |
| Fair Price | (4.56) - (4.62) | (4.59) |
| Upside | -751.5% - -760.2% | -756.0% |
| Date | EV/EBITDA |
| 2025-12-23 | -3.96 |
| 2025-12-22 | -4.29 |
| 2025-12-19 | -3.66 |
| 2025-12-18 | -3.70 |
| 2025-12-17 | -3.69 |
| 2025-12-16 | -3.67 |
| 2025-12-15 | -3.60 |
| 2025-12-12 | -3.88 |
| 2025-12-11 | -4.01 |
| 2025-12-10 | -3.75 |
| 2025-12-09 | -4.20 |
| 2025-12-08 | -4.08 |
| 2025-12-05 | -4.11 |
| 2025-12-04 | -4.15 |
| 2025-12-03 | -4.11 |
| 2025-12-02 | -4.29 |
| 2025-12-01 | -4.21 |
| 2025-11-28 | -4.51 |
| 2025-11-26 | -4.41 |
| 2025-11-25 | -4.63 |
| 2025-11-24 | -4.59 |
| 2025-11-21 | -4.00 |
| 2025-11-20 | -3.58 |
| 2025-11-19 | -3.67 |
| 2025-11-18 | -3.58 |
| 2025-11-17 | -3.75 |
| 2025-11-14 | -3.77 |
| 2025-11-13 | -3.80 |
| 2025-11-12 | -3.67 |
| 2025-11-11 | -3.95 |
| 2025-11-10 | -4.07 |
| 2025-11-07 | -4.00 |
| 2025-11-06 | -4.02 |
| 2025-11-05 | -4.18 |
| 2025-11-04 | -4.41 |
| 2025-11-03 | -4.36 |
| 2025-10-31 | -4.43 |
| 2025-10-30 | -4.36 |
| 2025-10-29 | -4.36 |
| 2025-10-28 | -4.63 |
| 2025-10-27 | -4.55 |
| 2025-10-24 | -4.70 |
| 2025-10-23 | -4.66 |
| 2025-10-22 | -4.70 |
| 2025-10-21 | -4.59 |
| 2025-10-20 | -4.70 |
| 2025-10-17 | -4.87 |
| 2025-10-16 | -4.97 |
| 2025-10-15 | -5.02 |
| 2025-10-14 | -5.05 |